Experimental muscle cell injection trial opens for duchenne patients

NCT ID NCT06692426

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether injecting lab-grown muscle cells (MyoPAXon) into the foot is safe for adults with Duchenne muscular dystrophy who can no longer walk. Eight participants will receive the cells along with an immunosuppressant drug to prevent rejection. The main goal is to find a safe dose, not to measure improvement.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MyoPAXon (iPSC-derived muscle progenitor cells) plus tacrolimus (immunosuppressant)
What this could lead to: If safe, this could pave the way for a treatment that helps repair muscle in people with Duchenne muscular dystrophy.
What could go wrong: This is a very early, small safety trial with only 8 participants. It is not designed to prove the treatment works, and participants must take lifelong immunosuppressants, which carry serious risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY

Contacts and locations

Locations

Masonic Cancer Center
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.